Ischaemia/Reperfusion Injury (IRI) is the most common cause of acute kidney injury- a devastating clinical problem lacking any specific treatments to promote renal recovery. Macrophages (Mφ) are pleiotropic cells of the innate immune system, with roles spanning host defence, cytotoxicity, clearance of apoptotic cells and promotion of tissue repair. Mφ are also known to be important mediators of renal injury in other experimental models of renal disease including transplantation, obstruction and glomerulonephritis. This work sought to examine the role of Mφ in mediating renal IRI. Conditional renal Mφ and monocyte depletion prior to experimental IRI was achieved by administering diphtheria toxin to the CD11b-DTR transgenic animal. This had no impact on either renal function or structural injury. In contrast liposomal clodronate mediated Mφ depletion provided functional and structural protection from injury. Administration of exogenous apoptotic cells also protected renal function if delivered 24h prior to IRI. Immunodeficient SCID mice exhibited a protected injury phenotype after IRI, however derived no additional protection from the administration of either liposomal clodronate or i.v. apoptotic cells. These findings suggest that the protective phenotype must involve either lymphocyte populations or circulating antibody. Preliminary work demonstrates that SCID mice lack IgM natural antibody which deposits in the kidney in the first 30 minutes after IRI. It was also demonstrated that apoptotic cells bind IgM natural antibody present within the circulation. The potential for the key antioxidant enzyme Heme oxygenase-1 (HO-1) to protect renal function was also examined in aged mice using hemearginate (HA) - a potent HO-1 inducer. Echoing epidemiological studies in humans aged mice had increased susceptibility to IRI, whilst failing to induce medullary HO-1. The main site of medullary HO-1 induction by HA was in medullary Mφ, and the protective phenotype was abolished by Mφ ablation, implicating Mφ as the key mediators of HA induced protection in renal IRI. Final studies employed adenoviral transduction to overexpress HO-1 within bone marrow derived Mφ, leading to a modified phenotype with increased IL- 10 and phagocytosis, and reduced TNFα and NO production. When these were introduced in vivo after IRI renal function was improved, potentially due to accelerated clearance of renal platelet deposition.

The endothelium plays a pivotal role in the maintenance of vascular homeostasis and its dysregulation promotes vascular complications. This thesis proposes that heme oxygenase-1 (HO-1), an anti-inflammatory enzyme with antioxidant properties, is endothelial protective factor that prevents endothelial injury induced by cisplatin or activated neutrophils. Specifically, this thesis aimed to test (i) that overexpression of HO-1 prevents cisplatin-induced endothelial injury and suppresses caspase activity; (ii) whether neutrophil-endothelial cell activation resulted in the release of soluble Flt-1 (sFlt-1) and soluble endoglin (sEng), the two anti-angiogenic factors known to induce the clinical signs of preeclampsia; (iii) whether HO-1 prevented activated neutrophils from stimulating the release of these factors from the endothelium; (iv) the relative contribution and the co-dependency of neutrophil activation and anti-angiogenic growth factors in preeclampsia where systemic endothelial dysfunction is known to occur. This thesis shows that cisplatin inhibited human umbilical vein endothelial cells (HUVEC) metabolism as measured by MTT assay and resulted in the release of placenta growth factor (PlGF). Immunoblotting confirmed that cisplatin increased cleaved caspase-3 expression in HUVEC. These effects of cisplatin were attenuated in HUVEC infected with adenovirus encoding HO-1 and the effects were exacerbated when HO-1 was silenced by siRNA. Furthermore, cisplatin stimulated PlGF release was suppressed by the overexpression of HO-1. In addition, HO-1 overexpression inhibited angiogenesis as determined by vascular endothelial growth factor-induced capillary tube formation on Matrigel coated plates. Thus these studies indicate that agents which upregulate HO-1 could increase the effectiveness and tolerability to cisplatin in cancer treatment. Although neutrophils are early contributors to endothelial cell activation, no studies have determined their contribution to the release of sFlt-1 and sEng. We therefore investigated the effect of activated neutrophils on the release of sFlt-1 and sEng in endothelial/neutrophil co-cultures and in the circulation of women with normal pregnancy and preeclampsia. LPS-mediated neutrophil activation stimulated the release of sEng but not sFlt-1 from endothelial cells in culture. In the absence of neutrophils, overexpression of HO-1 in HUVEC downregulated the release of sEng. In contrast, HO-1 overexpression failed to inhibit the release of sEng in the presence of activated neutrophils. The release of sEng by activated neutrophils-endothelial cell cocultures appears to be mediated by metalloproteinases (MMP) as the broad-spectrum MMP inhibitor (GM6001) attenuated sEng release. Clinical studies demonstrated that sEng, pro-inflammatory interleukin-6 (IL-6) and the soluble markers of neutrophil activation (α-defensins and calprotectin) were all elevated in women with preeclampsia. We identified a direct correlation between neutrophil activation and IL-6 release. However, no correlation could be established between these factors and sEng release in preeclampsia. Hence, these results provide compelling clinical evidence to show that the increase in neutrophil activation and IL-6 release during preeclampsia are unlikely to significantly contribute to the clinical signs of preeclampsia as they fail to correlate directly with the anti-angiogenic factors, which form the final common pathway to the clinical signs of preeclampsia and systemic endothelial dysfunction.

In 2007, a gene homolog of CDO encoded by the gene Gm237 in the DUF164 family was identified as cysteamine dioxygenase (ADO). ADO is one of the only known thiol dioxygenases found in mammals. Both ADO and its partner cysteine dioxygenase (CDO) are non-heme iron dependent enzymes that play a crucial role in the biosynthesis of taruine/hypotaurine by insertion of a dioxygen molecule. However, ADO has been overshadowed by CDO as heavy research focus on CDO over the past decade has led to the elucidation of its structure and possible mechanistic properties. In an effort to further understand ADO’s mechanism and regulating role in vivo, this work will be focused on the mammalian hADO and trying to gain further insight on hADO’s structural features via crystallography work. Investigation of the crystallization parameters for hADO has elucidated several potential conditions. Detailed work on these crystallization parameters will be presented.

Orientador: Valeria Cristina Sandrim / Resumo: Distúrbios hipertensivos da gravidez (HPD) são caracterizados por aumento de pressão arterial após a 20ª semana gestacional; a presença de proteinuria e/ou sinais de danos a órgãos como fígado, rins e sistema nervoso central indicam pré-eclâmpsia (PE). Estes distúrbios afetam de 5 a 7% das gestações ao redor do mundo e ainda que uma causa única não tenha sido identificada, o processo de placentação insuficiente se mostra crucial para o desenvolvimento destas afecções. A placenta isquêmica e disfuncional secreta moléculas que irão afetar o endotélio, tecido que reveste os vasos internamente, e este responde de inúmeras maneiras com o intuito de manter a homeostasia. A enzima heme-oxigenase 1 tem um papel importante na manutenção da função endotelial ao converter grupos heme em moléculas antioxidantes, antiapoptóticas e vasoativas. Foi reportado que a produção de heme-oxigenase 1 pode ser estimulada pelo iodeto de potássio (KI) em queratinócitos, bem como fragmentos de pele humana. Neste estudo células endoteliais de veia umbilical humana (HUVEC’s) foram incubadas com plasma de mulheres grávidas apresentando HPD com o objetivo de avaliar o potencial do KI de estimular a expressão da heme-oxigenase 1 nestas células. Os resultados mostram que o KI foi capaz de induzir a expressão da enzima no grupo saudável (p=0,0065) e de reduzi-la a níveis normais no grupo hipertenso (p=0,0018); o tratamento reduziu a citotoxicidade do plasma de grávida pré-eclâmpticas sobre as HUVEC’s, mas não... (Resumo completo, clicar acesso eletrônico abaixo) / Mestre

Orientador: Valéria Cristina Sandrim / Resumo: A pré-eclâmpsia (PE) é a principal causa de mortalidade e morbidade entre as gestantes no Brasil e em vários países. A fisiopatologia desta doença é complexa e envolve vários processos. Um destes, amplamente validado na literatura, relaciona-se a um status oxidativo, onde há prevalência de produção de radicais livres e/ou redução da atividade antioxidante. Apesar destas evidências, a suplementação clínica com antioxidantes (vitamina C e E) não se demonstrou promissora em PE. Recentemente, vem sendo explorado como terapia em várias doenças, a ativação de um fator de transcrição, o NRF2 (do inglês - nuclear factor, erythroid 2-like 2), que atua induzindo a transcrição de diversos genes que promovem a proteção celular através da codificação de proteínas com atividade desintoxicante e antioxidante. Entre elas a heme oxigenase (HO-1) é a mais estudada, pois apresenta efeitos antiapoptóticos, antioxidantes e citoprotetor. Além disso, o aumento do estresse oxidativo na PE pode potencialmente reduzir a biodisponibilidade de óxido nítrico (NO) que pode ser modulado por alguns polimorfismos localizados no gene da óxido nítrico sintase (NOS3). Notavelmente, os haplótipos formados pela combinação de polimorfismos foram associados a diferentes subgrupos de resposta à terapia anti-hipertensiva em PE. No presente estudo, comparamos as distribuições dos polimorfismos localizados nos genes NFE2L2 rs35652124 (C/T) e no gene HMOX1 rs2071746 (A/T) em gestantes com PE que respondem à metildopa ou... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Preeclampsia (PE) is the leading cause of mortality and morbidity among pregnant women in Brazil and several countries. Its pathophysiology is complex and involves several processes, including the oxidative stress (increase of free radicals and/or decrease of antioxidant defense). Although evidences, clinical supplementation with vitamins (C and E) was not promising in preeclampsia. Currently, therapeutically the activation of transcription factor, NRF2 (nuclear factor, erythroid 2-like 2), has been explored in several diseases. This factor promote cytoprotection by activates the transcription of several antioxidant and detoxification proteins. Hemeoxigenase-1 (HO-1) is the most studied, because has antiapoptotic, anti-inflammatory and cytoprotection activities. In addition, the increased oxidative stress in PE can potentially reduce the bioavailability of nitric oxide (NO) which may impaired by some SNPs on endothelial nitric oxide synthase (NOS3) gene. Notably, haplotypes formed by the combination of polymorphisms of were associated with different subgroups of response to antihypertensive therapy in PE. Therefore, in the present study we compared the distributions of rs35652124 (C/T) NFE2L2 and rs2071746 (A/T) HMOX1 polymorphisms in PE patients who respond to methyldopa or antihypertensive therapy with those found in PE patients who do not respond to methyldopa or total antihypertensive therapy. We also examined whether NFE2L2 and HMOX1 polymorphisms affect plasma HO-1 leve... (Complete abstract click electronic access below) / Mestre

Heme Oxygenase (HO) is an enzyme universally found in animals, plants and microbes. In plants, the role of heme oxygenase in the synthesis of the phytochrome chromophore is well recognized and has been extensively studied; however its role in regulating reactive oxygen species (ROS) in plants is just beginning to be explored, particularly in legumes. Legumes interact with Rhizobium bacteria to form symbiotic nitrogen fixing nodules. ROS plays an important role in the development of roots as well as symbiotic nodules. In the model legume Medicago truncatula, ROS in the root is regulated in part by the LATD/NIP gene. The M. truncatula giraffe mutant has a deletion that removes the entire HO coding sequence. We have found that the M. truncatula GIRAFFE HO regulates expression of some of the LATD/NIP-regulated ROS genes such as RESPRATORY BURST OXIDASE HOMOLOG C (RBOHC) and a cell wall peroxidase (cwPRX2) in seedlings. This means that the wild-type function of GIRAFFE is to up-regulate expression of RBOHC and cwPRX2 in roots, in contrast to LATD/NIP, which down-regulates them. We also found that LATD/NIP and GIRAFFE do not regulate expression of each other in seedlings. Given that the highest expression of GIRAFFE HO is in a senescing nodule, we tested the expression of ROS-regulatory enzymes in senescing nodules. We found that GIRAFFE up-regulates expression of RBOHC during nitrate-induced nodule senescence. At present, with changing climatic conditions and exposure to various environmental stresses that can alter ROS homeostasis, characterizing the role of GIRAFFE in the antioxidant machinery of legumes can be useful in improving crop productivity and for enhancing soil fertility.

IsdG and IsdI are non-canonical heme oxygenases (HO) from Staphylococcus aureus that catalyze the oxidative cleavage of heme to give novel organic products (staphylobilins) and iron as a nutrient for the pathogen. Comparison of the reported equilibrium dissociation constant (Kd) values for heme from IsdG and IsdI compared to the reported concentration of the labile heme pool called into question whether these enzymes are competent HOs in vivo. We took advantage of a second-sphere Trp whose fluorescence is quenched upon heme binding, which led to Kd values 2-3 orders of magnitude smaller than reported in the literature. Importantly, these Kd values were on the same order of magnitude as human HO, precluding design of a competitive inhibitor as an effective therapeutic. Based upon the kinetic and equilibrium data, and the finding that the half-life of IsdG is increased 2.5-fold by the presence of heme, we proposed IsdG is the main HO involved in iron acquisition which motivated further characterization of IsdG. IsdG-catalyzed heme catabolism proceeds through ferric-peroxoheme and meso-hydroxyheme intermediates en route to staphylobilin. A second-sphere Asn is known to be critical for enzymatic function, but its role in heme cleavage was unknown. Site-directed mutagenesis was employed to probe the role of Asn using ferric-azidoheme and ferric-cyanoheme as models of the putative ferric-peroxoheme intermediate. An optical spectroscopic study established that a hydrogen-bond between Asn and the iron-ligating (α) atom of the distal ligand perturbs the heme electronic structure. Density functional theory (DFT) suggested this hydrogen-bond triggers rotation of the distal ligand, which was corroborated by circular dichroism (CD), and delocalizes spin density onto the meso carbons. Electron paramagnetic resonance (EPR) revealed the Asn hydrogen-bond increases the Fe 3dxy character in the singly occupied molecular orbital (SOMO), a mechanism that can increase spin density on the meso carbons. Finally, the Asn hydrogen-bond moves the meso carbon resonances downfield in the 13C nuclear magnetic resonance (NMR) spectrum, consistent with excess spin density, confirming a DFT-predicted, Asn-induced spin delocalization. These results suggest IsdG funnels the reactivity of ferric-peroxoheme toward heme hydroxylation through an Asn-dependent bridged transition state, circumventing production of reactive, uncontrolled intermediates.

Includes bibliography / 100 leaves, [8] leaves of plates : ill ; 30 cm. / Title page, contents and abstract only. The complete thesis in print form is available from the University Library. / Thesis (Ph.D.)--University of Adelaide, Dept. of Biochemistry, 1987

The disruption of the blood-brain barrier (BBB) occurs after ischemic and hemorrhagic stroke and contributes to secondary brain damage. Matrix metalloproteinase-9 (MMP9) has been identified to be the main mediator of post-stroke BBB disruption. It is unknown whether deposition of heme/iron in the brain following stroke would affect MMP9 expression. In this study, I have demonstrated that heme/iron up-regulated MMP9 expression in rat astrocytes and that this upregulation was most likely due to reactive oxygen species (ROS) generated by heme/iron deposition on cells. ROS can activate AP-1 and NFκB signaling pathways which were responsible for increased MMP9 expression. Inhibiting AP-1 and NFκB decreased MMP9 expression. Heme/iron deposition also activated Nrf-2 and increased the expression of neuroprotective heme oxygenase-1. My study suggests that heme and iron deposition generates ROS and increases MMP9 expression through AP-1 and NFκB signaling pathways and that targeting these pathways or clearance of heme and iron may modulate MMP9 expression for reduced damage.

Nuclear receptors (NR’s) comprise a large, ancient, superfamily of eukaryotic transcription factors that govern a wide range of metabolic, homeostatic, and developmental pathways, and which have been implicated in disease states including cancer, inflammation, and diabetes. The ability of NRs to activate or repress gene transcription is modulated through direct binding of small lipophilic ligands which induce conformational changes in their cognate receptor. These changes are structural in nature and lead to the recruitment of coactivator or corepressor complexes, ultimately regulating the expression of target genes to whose response elements NRs are bound. In Drosophila 18 NRs have been identified which have representative members belonging to each of the six major NR subfamilies, and which show a high degree of homology to their vertebrate counterparts. This fact, in addition to the power and ease of genetic manipulation, make Drosophila an excellent model system in which to study NR function. When I began my project, 17 of the 18 NRs in Drosophila were ‘orphan’ receptors for which no cognate ligand had been identified. As a first step in an effort to identify potential ligands for these 17 receptors I first set out to determine how, where and when nuclear receptors are regulated by small chemical ligands and/or their protein partners. In order to do so I contributed to developing a ‘ligand sensor’ system to visualize spatial activity patterns for each of the 18 Drosophila nuclear receptors in live, developing animals. This system is based upon transgenic lines that express the ligand binding domain of each Drosophila NR fused to the DNA-binding domain of yeast GAL4. When combined with a GAL4-responsive reporter gene, these fusion proteins show tissue- and stage-specific patterns of activation. Analysis using this system has revealed the stage and tissue specificity of NR activation for each of the fly NRs. The amnioserosa, yolk, midgut and fat body, which play major roles in lipid storage, metabolism and developmental timing, were identified as frequent sites of nuclear receptor activity. Dynamic changes in activation that are indicative of sweeping changes in ligand and/or co-factor production are also a prominent feature that has been revealed using this approach. In addition, I went on to characterize the ligand regulated function of a single Drosophila nuclear receptor, Ecdysone inducible protein 75 (E75). Previous work from our lab has demonstrated that E75 binds to heme, and that its function as a transcriptional repressor is regulated in vitro by binding of the small diatomic gases nitric oxide (NO) and carbon monoxide (CO) to its heme moiety. In an effort to validate and to further understand the in vivo relevance of E75 regulation by NO I used gain and loss of function transgenes, as well as tissues manipulated in culture to show that NO acts directly on the Drosophila nuclear receptor E75, reversing its ability to block the activity of its heterodimer partner Drosophila Hormone Receptor 3 (DHR3). By specifically focusing on the Drosophila larval ring gland, the principal endocrine organ responsible for the production of the metamorphosis-inducing hormone, ecdysone, I have shown that failure to produce NO and to inactivate E75 results in failure to recognize the signals that normally trigger metamorphosis.